Advanced colorectal cancer is the first tumor type for which an antiangiogenic agent, namely bevacizumab, has been approved by the Food and Drug Administration for therapy in humans; it has been in use since February 2004. This review paper summarizes and discusses the results obtained with this agent and highlights the main open or controversial issues on antiangiogenic therapy, taking into account that the clinical results obtained are below the expectations, particularly in the adjuvant setting.
HurwitzH., FeherenbacherL., NovotnyW.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004; 350: 2335–42.
3.
RothenbergM.L., OzaA.M., BigelowR.H.. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.J Clin Oncol2003; 21: 2059–69.
4.
de GramontA., FigerA., SeymourM.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol2000; 18: 2938–47.
5.
GoldbergR.M., SargentD.J., MortonR.F.. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combination in patients with previously untreated metastatic colorectal cancer.J Clin Oncol2004; 22: 23–30.
6.
CunninghamD., PyrhönenS., JamesR.D.. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet1998; 352: 1413–8.
7.
SaltzL.B., CozJ.V., BlankeC.. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med2000; 343: 905–14.
8.
GiantonioB.J., CatalanoP.J., MeropolN.J.. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200.J Clin Oncol2007; 25: 1539–44.
9.
ZirasN., PolyzosA., KakolyrisS.. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): interim analysis for safety of a randomized phase III trial.J Clin Oncol2008; 26(Suppl): abstr 15008.
NeugutA.I., BeckerD.J., BuonoD., KershenbaumA., HerschmanD.L.. Off-label approved use of bevacizumab in elderly patients with colon cancer.J Clin Oncol2010; 28(Suppl): abstr e14038.
14.
ChongG., TebbuttN.C.. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity.Ther Advanc Med Oncol2010; 2: 309–17.
15.
PriceT.J., ZanninoD., WilsonK.. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomized controlled trial of capecitabine, bevacizumab and mitomycin C.Ann Oncol2012; 23: 1531–6.
16.
VenderboschS., DoornebalJ., TeerenstraS., LemmensW., PuntC.J., KoopmanM.. Outcome of first-line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).Acta Oncol2012; 51: 831–9.
17.
HurwitzH.I., YiJ., InceW., NovotnyW.F., RosenO.. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.Oncologist2009; 14: 22–8.
18.
CassidyJ., ClarkeS., Diaz-RubioE.. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.Br J Cancer2011; 105: 58–64.
19.
TolJ., KoopmanM., CatsA.. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.N Engl J Med2009; 360: 563–72.
20.
HechtJ.R., MitchellE., ChidiacT.. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.J Clin Oncol2009; 27: 672–80.
21.
Van CutsemE., NowackiM., LangI.. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL STUDY.J Clin Oncol2007; 25(Suppl): abstr 4000.
22.
BokemeyerC., BondarenkoI., MakhsonA.. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol2009; 27: 663–71.
23.
MaughanT.S., AdamsR.A., SmithC.G.. Addition of cetuximab to oxaliplatin-based first-line combinations chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Lancet2011; 377: 2103–14.
24.
DouillardJ.Y., SienaS., CassidyJ.. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol2010; 28: 4697–705.
25.
WongR., CunninghamD., BarbachanoY.. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.Ann Oncol2011; 22: 2042–8.
26.
HurwitzH.I., FehrenbacherL., HaisworthJ.D.. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.J Clin Oncol2005; 23: 3502–8.
27.
SaltzL.B., ClarkeS., Diaz-RubioE.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.J Clin Oncol2008; 26: 2013–19.
28.
TebbuttN.C., WilsonK., GebskiV.J.. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study.J Clin Oncol2010; 28: 3191–8.
29.
Van CutsemE., RiveraF., BerryS.. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.Ann Oncol2009; 20: 1842–7.
30.
KozloffM., YoodM.U., BerlinJ.. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal study: the BriTE observational cohort study.Oncologist2009; 14: 862–70.
31.
Bekaii-SaabT.S., GrotheyA., BendellJ.C.. Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): results from the ARIES observational cohort study.J Clin Oncol2012; 4(Suppl): abstr 535.
32.
AllegraC.J., YothersG., O'ConnellJ.. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.J Clin Oncol2011; 29: 11–6.
33.
De GramontA., Van CutsemE., TaberneroJ.. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.J Clin Oncol2011; 29(Suppl): abstr 362.
34.
Quasar Collaborative Group; GrayR., BarnwellJ., McCon-keyC., HillsR.K., WilliamsN.S., KerrD.J.. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.Lancet2007; 370: 2020–9.
35.
ECOG-E 5202, NCT 00217737.Phase III randomized study of oxaliplatin, leucovorin calcium, and fluorouracil with or without bevacizumab in patients with resected stage II colon cancer and at high risk for recurrence based on molecular markers.http://www.clinicaltrials.gov/show/NCT00217737.
36.
WillettC.G., DudaD.G., di TomasoE.. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.J Clin Oncol2009; 27: 3020–26.
37.
CraneC.H., EngC., FeigB.W.. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.Int J Radiat Oncol Biol Phys2010; 76: 824–30.
38.
VelenikV., OcvirkJ., MusicM.. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.Radiation Oncol2011; 6: 105.
39.
KoukourakisM.I., GiatromanolakiA., TsoutsouP.. Bevacizumab, capecitabine, amifostine, and preoperative hypo-fractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study.Int J Radiat Oncol Biol Phys2011; 80: 492–8.
40.
ReschG., De VriesA., OfnerD.. Preoperative treatment with capecitabine, bevacizumab, and radiotherapy for primary locally advanced rectal-cancer–a two stage phase II clinical trial.Radiother Oncol2012; 102: 10–3.
41.
DipetrilloT., PricoloV., Lagares-GarciaJ.. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.Int J Radiat Oncol Biol Phys2012; 82: 124–9.
42.
SpigelD.R., BendellJ.C., McCleodM.. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.Clin Colorectal Cancer2012; 11: 45–52.
43.
KenneckeH., BerryS., WongR.. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.Eur J Cancer2012; 48: 37–45.
44.
GaspariniG., TorinoF., UenoT.. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.Angiogenesis2012; 15: 141–50.
45.
Martinez VillacampaM., CapdevilaJ., ManzanoJ.L.. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer.J Clin Oncol2012; 30(Suppl): abstr 3571.
46.
NoguéM., SaludA., VicenteP.. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based CRT in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.Oncologist2011; 16: 614–20.
47.
KumarR., KnickV.B., RudolphS.K.. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.Mol Cancer Ther2007; 6: 2012–21.
48.
LongoR., GaspariniG.. Challenges for patient selection with VEGF inhibitors.Cancer Chemother Pharmacol2007; 60: 151–70.
49.
LongoR., GaspariniG.. Anti-VEGF therapy: the search for clinical biomarkers.Expert Rev Mol Diagn2008; 8: 301–14.
50.
XuC.F., BingN.X., BallH.A.. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.J Clin Oncol2011; 29: 2557–64.
51.
AbajoA., BoniV., LopezI.. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.Br J Cancer2012; 107: 287–90.
52.
ManzoniM., MariucciS., DelfantiS.. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer.J Cancer Res Clin Oncol2012; 138: 1187–96.
53.
PohlA., El-KhoueiryA., YangD.. Pharmacogenetic profiling of CD 133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.Pharmacogenomics J2012; doi: 10.1038/tpj.2011.61. [Epub ahead of print].
54.
HansenT.F., ChristensenRd, AndersenR.F., Garm SpindlerK.L., JohnssonA., JakobsenA.. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.Int J Colorectal Dis2012; 27: 715–20.
55.
Van CutsemE., LangI., FolprechtG.. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial.J Clin Oncol2010; 28(suppl), abstr 281.
56.
ToffoliG., CecchinE., GaspariniG.. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.J Clin Oncol2010; 28: 866–71.
57.
ZulatoE., CurtarelloM., NardoG., IndraccoloS.. Metabolic effects of anti-angiogenic therapy in tumors.Biochimie2012; 94: 925–31.
58.
NardoG., FavaroE., CurtarelloM.. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.Cancer Res2011; 71: 4214–25.
